Zydus aflibercept
Aflibercept biosimilar developed by Zydus Lifesciences. Reference product Eylea.
About Zydus aflibercept
Zydus received the first Indian permission for a domestically made aflibercept, in June 2025, covering wet macular degeneration and the diabetic and vein occlusion uses. Zydus has also taken its ranibizumab to the United States.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Zydus aflibercept holds an approval, these are the other aflibercept biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 1 | Biocon Biologics (Yesafili) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Zydus Lifesciences: Exemptia / Cadalimab, Nufymco, Zydus bevacizumab, Zydus epoetin, Zydus follitropin alfa, Zydus peginterferon alfa-2b, Zydus pertuzumab, Zydus rituximab, Zydus teriparatide, Zydus trastuzumab.
Chronology
- CDSCOJun 2025CDSCO permission granted
Sources
Planning aflibercept biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant